Celularity Warns on Survival After 66% Revenue Decline

Celularity Warns on Survival After 66% Revenue Decline Celularity’s first-quarter revenue fell 66.2% year-over-year to $2.4 million, according to its May 15 quarterly filing with the Securities and Exchange Commission. The cash-burning biotech company explicitly stated these results “raise substantial doubt about the Company’s ability to continue as a going concern,” prompting it to divest its biomaterials business to conserve capital for its core cell therapy programs. ## Background Celularity, which went public via a Special Purpose Acquisition Company (SPAC) merger in 2021, develops therapies from postpartum placentas. The market backdrop for capital-intensive, pre-profitability biotechs has deteriorated significantly since the zero-interest-rate era that fueled the SPAC boom. With an accumulated deficit of nearly $800 million, Celularity’s financial state is precarious. Its stock has collapsed more than 99% from its post-merger highs, a common trajectory for companies that came to market through SPACs with optimistic long-term projections but little revenue. The company’s latest quarterly print continues a trend of operational losses and dwindling cash. The “going concern” warning is a formal declaration in financial statements indicating that a company may not have sufficient cash to meet its obligations over the next year. To address this, on April 1, Celularity transferred its biomaterials product and distribution business to a subsidiary of NexGel, Inc. This move is designed to narrow the company’s focus and reduce its cash burn rate, redirecting scarce resources toward its more speculative, but potentially higher-value, cell therapy pipeline. ## Why it matters The situation at Celularity is a direct read-through for the dozens of other small-cap biotech and health-tech firms that lack a clear path to profitability. The market is no longer funding long-shot science projects on the same terms it did three years ago. Access to capital has tightened, and investors now demand clearer, shorter timelines to commercial viability or positive cash flow. Companies that cannot meet this higher bar are being forced into distress sales, radical restructurings, or insolvency. Investors who held on to post-SPAC biotech stocks are on the wrong side of this macro shift. The pressure is most acute for companies like Celularity, which compete in capital-intensive fields like cell therapy. While its placental technology platform may hold scientific promise, the immediate financial realities have taken precedence. The divestiture to NexGel highlights a survival strategy: shed any revenue-generating but non-core assets to fund the primary research and development effort, effectively trading a small, certain present for an uncertain, potentially larger future. This is a bet on the core science that the market is currently unwilling to underwrite. ## What to watch The company's survival now depends on its ability to secure new capital. Watch for any announcement regarding a financing round, a strategic partnership that includes an upfront cash payment, or further asset sales by August 15, 2024, when its second-quarter results will provide the next formal update. If Celularity secures significant new funding or a major development deal, it could secure its operations for several more quarters. If it fails to do so, expect to see further operational cutbacks, a failure to meet NYSE listing requirements, or a more drastic strategic action to avoid bankruptcy.